Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2025 Financial Call.
Celcuity Inc. (CELC)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,915,792 | $789,521,094 | 4.62% | |
| 2. | Perceptive Advisors Joseph Edelman | 3,160,200 | $315,198,348 | +7% | 5.62% |
| 3. | VenBio Select Advisor Kurt Von Emster | 3,111,111 | $310,302,211 | 3.05% | |
| 4. | Soleus Capital Guy Levy | 1,808,258 | $180,355,653 | +54% | 6.65% |
| 5. | Deerfield Management James E. Flynn | 1,714,000 | $170,954,360 | +134% | 2.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $58.02 | 4,212 | $244,395.40 | 7,211,484 | 2025-09-08 | Filing | |
| $58.02 | 388 | $22,513.16 | 704,308 | 2025-09-08 | Filing | |
| $56.22 | 151,524 | $8,518,679.28 | 7,207,272 | 2025-09-08 | Filing | |
| $56.22 | 13,976 | $785,730.72 | 703,920 | 2025-09-08 | Filing | |
| $10.32 | 10,000 | $103,187.00 | 10,250 | 2023-05-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $110.83 | 675 | $74,808.09 | 6,760 | 2026-03-31 | Filing | |
| $110.11 | 2,325 | $255,995.75 | 7,435 | 2026-03-31 | Filing | |
| $120.03 | 20,000 | $2,400,538.00 | 90,000 | 2026-01-27 | Filing | |
| $106.04 | 1,510 | $160,113.30 | 6,760 | 2025-12-05 | Filing | |
| $105.34 | 1,490 | $156,956.30 | 8,270 | 2025-12-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,796 | $1,779,103 | 0% | |
| 2. | 153,000 | $372,249 | 0.05% | |
| 3. | 2,639 | $301,215 | 0.02% | |
| 4. | 1,604 | $183,081 | 0.02% | |
| 5. | 1,099 | $125,440 | 0.01% |
News See All
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Wells Fargo Initiates Coverage On Celcuity Inc. (CELC)
On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating.
Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results
In an updated report which was presented to the 2025 San Antonio Breast Cancer Symposium early last month, Celcuity Inc.
Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View
Celcuity Inc. (NASDAQ:CELC) is among the hottest SMID-cap stocks so far in 2025.
10 Hottest SMID-Cap Stocks So Far In 2025
SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.
Celcuity Inc. (NASDAQ:CELC) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2025 Financial Results Webcast and Conference Call. At this time, all lines are in listen-only mode.
Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result
This followed announcements that its drug candidate—gedatolisib, in combination with two other drugs (called the triplet)—showed a marked 76 percent reduction in the disease progression of enrolled...
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review
Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company developing targeted oncology therapies, with a focus on solid tumors such as advanced breast cancer.